Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

29 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Study Completion Date

2017-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The prevalence of methicillin resistant Staphylococcus aureus (MRSA) respiratory infection in Cystic Fibrosis (CF) has increased dramatically over the last decade. Evidence suggests that persistent infection with MRSA may result in an increased rate of decline in Forced Expiratory Volume (FEV)1 and shortened survival. Currently there are no conclusive studies demonstrating an effective aggressive treatment protocol for persistent MRSA respiratory infection in CF. Data demonstrating an effective and safe method of clearing persistent MRSA infection are needed.

The purpose of this study is to evaluate the safety and efficacy of a 28-day course of vancomycin for inhalation, 250 mg twice a day, (in combination with oral antibiotics) in eliminating MRSA from the respiratory tract of individuals with CF and persistent MRSA infection. Subjects will be assigned in a 1:1 ratio to either vancomycin for inhalation (250 mg twice a day) or taste matched placebo and will be followed for 3 additional months. In addition, both groups will receive oral rifampin, a second oral antibiotic (TMP-SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Forty patients with persistent respiratory tract MRSA infection will be enrolled in this trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)

NCT01349192

Cystic Fibrosis Methicillin-resistant Staphylococcus Aureus

TERMINATED PHASE2

STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)

NCT03489629

Cystic Fibrosis

ACTIVE_NOT_RECRUITING PHASE2

Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF)

NCT02684422

Methicillin-Resistant Staphylococcus Aureus Cystic Fibrosis

COMPLETED

Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"

NCT00729937

Staphylococcal Infection

COMPLETED PHASE2/PHASE3

Stop Community MRSA Colonization Among Patients

NCT02029872

MRSA

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Objectives

The primary objectives of this trial are to:

1. Determine the efficacy of an aggressive treatment protocol in eradicating persistent MRSA infection in individuals with CF.
2. Determine the safety of an aggressive treatment protocol in eradicating persistent MRSA infection in individuals with CF.

Secondary Objectives

The secondary objectives of this trial are to:

1. Determine the efficacy of an aggressive treatment protocol in improving Forced Expiratory Volume (FEV)1, time to exacerbation, and quality of life in individuals with CF and persistent MRSA infection.
2. Determine if there is benefit to adding nebulized vancomycin to an aggressive oral antibiotic treatment protocol in eradicating persistent MRSA infection in individuals with CF.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Inhaled Vanc and Oral Abx

In the experimental arm CF participants are randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.

Group Type EXPERIMENTAL

Inhaled Vancomycin

Intervention Type DRUG

On Days 1-28, subjects will receive nebulized Vancomycin. This will be supplied as a 250 mg solution to be nebulized two times a day for 28 days in 5cc sterile water. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.

Rifampin

Intervention Type DRUG

Oral Rifampin by mouth for 28 days

1. \>45 kg: 600 mg by mouth daily
2. 35-45 kg : 450 mg by mouth daily
3. 25-34.9 kg: 300 mg by mouth daily

Trimethoprim/Sulfamethoxazole (TMP/SMX)

Intervention Type DRUG

Oral trimethoprim/sulfamethoxazole (DS-160/800)

1. \>45 kg: two DS tablets twice a day by mouth (320/1600)
2. 25-45 kg: one DS tablet twice a day by mouth (160/800)

Doxycycline

Intervention Type DRUG

If sulfa intolerant or TMP/SMX Resistant, use instead oral doxycycline

1. \>45 kg: 100 mg by mouth twice a day
2. 35-45 kg : 75 mg by mouth twice a day iii. 25-34.9 kg: 50 mg by mouth twice a day

Mupirocin Intranasal Creme

Intervention Type DRUG

Mupirocin 2% intranasal creme: half of single use tube applied into each nostril twice a day for 5 days.

4% chlorhexidine gluconate liquid skin cleanser

Intervention Type DRUG

Hibiclens 15cc liquid skin cleanser packets (4% chlorhexidine gluconate): use three packets once weekly for four weeks in the shower from the neck to toes, with attention on the axilla, groin, and buttocks.

Inhaled Placebo and Oral Abx

In the active comparator arm CF participants are randomized to 28 days of inhaled sterile placebo (saline) and are treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.

Group Type ACTIVE_COMPARATOR

Placebo (Sterile Water)

Intervention Type DRUG

On Days 1-28, subjects will receive 5cc of a nebulized Placebo (Sterile water) twice a day. This is a taste (quinine 0.1mg/mL) matched nebulized placebo (sterile water). Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.

Rifampin

Intervention Type DRUG

Oral Rifampin by mouth for 28 days

1. \>45 kg: 600 mg by mouth daily
2. 35-45 kg : 450 mg by mouth daily
3. 25-34.9 kg: 300 mg by mouth daily

Trimethoprim/Sulfamethoxazole (TMP/SMX)

Intervention Type DRUG

Oral trimethoprim/sulfamethoxazole (DS-160/800)

1. \>45 kg: two DS tablets twice a day by mouth (320/1600)
2. 25-45 kg: one DS tablet twice a day by mouth (160/800)

Doxycycline

Intervention Type DRUG

If sulfa intolerant or TMP/SMX Resistant, use instead oral doxycycline

1. \>45 kg: 100 mg by mouth twice a day
2. 35-45 kg : 75 mg by mouth twice a day iii. 25-34.9 kg: 50 mg by mouth twice a day

Mupirocin Intranasal Creme

Intervention Type DRUG

Mupirocin 2% intranasal creme: half of single use tube applied into each nostril twice a day for 5 days.

4% chlorhexidine gluconate liquid skin cleanser

Intervention Type DRUG

Hibiclens 15cc liquid skin cleanser packets (4% chlorhexidine gluconate): use three packets once weekly for four weeks in the shower from the neck to toes, with attention on the axilla, groin, and buttocks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Inhaled Vancomycin

On Days 1-28, subjects will receive nebulized Vancomycin. This will be supplied as a 250 mg solution to be nebulized two times a day for 28 days in 5cc sterile water. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.

Intervention Type DRUG

Placebo (Sterile Water)

On Days 1-28, subjects will receive 5cc of a nebulized Placebo (Sterile water) twice a day. This is a taste (quinine 0.1mg/mL) matched nebulized placebo (sterile water). Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.

Intervention Type DRUG

Rifampin

Oral Rifampin by mouth for 28 days

1. \>45 kg: 600 mg by mouth daily
2. 35-45 kg : 450 mg by mouth daily
3. 25-34.9 kg: 300 mg by mouth daily

Intervention Type DRUG

Trimethoprim/Sulfamethoxazole (TMP/SMX)

Oral trimethoprim/sulfamethoxazole (DS-160/800)

1. \>45 kg: two DS tablets twice a day by mouth (320/1600)
2. 25-45 kg: one DS tablet twice a day by mouth (160/800)

Intervention Type DRUG

Doxycycline

If sulfa intolerant or TMP/SMX Resistant, use instead oral doxycycline

1. \>45 kg: 100 mg by mouth twice a day
2. 35-45 kg : 75 mg by mouth twice a day iii. 25-34.9 kg: 50 mg by mouth twice a day

Intervention Type DRUG

Mupirocin Intranasal Creme

Mupirocin 2% intranasal creme: half of single use tube applied into each nostril twice a day for 5 days.

Intervention Type DRUG

4% chlorhexidine gluconate liquid skin cleanser

Hibiclens 15cc liquid skin cleanser packets (4% chlorhexidine gluconate): use three packets once weekly for four weeks in the shower from the neck to toes, with attention on the axilla, groin, and buttocks.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vanc Placebo Rifadin Bactrim Septra Vibramycin Adoxa Bactroban Hibiclens

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female ≥ 12 years of age.
2. Confirmed diagnosis of CF based on the following criteria:

positive sweat chloride \> 60 mEq/liter (by pilocarpine iontophoresis) and/or a genotype with two identifiable mutations consistent with CF or abnormal Nasal Potential Difference (NPD), and one or more clinical features consistent with the CF phenotype.
3. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
4. Two positive MRSA respiratory cultures in the last two years at least six months apart, plus a positive MRSA respiratory culture at Screening Visit and Run-in (Day -14) Visit.
5. At least 50% of respiratory cultures from the time of the first MRSA culture (in the last two years) have been positive for MRSA.
6. Forced Expiratory Volume (FEV)1 \> 40% of predicted normal for age, gender, and height at Screening, for subjects 18 years of age or older..
7. FEV1\> 60% of predicted normal for age, gender, and height at Screening, for subjects 12--17 years of old.
8. Females of childbearing potential must agree to practice one highly effective method of birth control, including abstinence. Note: highly effective methods of birth control are those, alone or in combination, that result in a failure rate less than 1% per year when used consistently and correctly. Female patients who utilize hormonal contraceptives as a birth control method must have used the same method for at least 3 months before study dosing. If the patient is using a hormonal form of contraception, patients will be required to also use barrier contraceptives as rifampin can affect the reliability of hormone therapy. Barrier contraceptives such as male condom or diaphragm are acceptable if used in combination with spermicides

Exclusion Criteria

1. An acute upper or lower respiratory infection, pulmonary exacerbation, or change in routine therapy (including antibiotics) for pulmonary disease within 42 days of the Day 1 Visit (2 weeks prior to Screening visit).
2. Individuals on chronic continuous inhaled antibiotics without interruption who are not willing to substitute vancomycin or placebo for their scheduled inhaled antibiotic during days 0-28 of the study (every other month inhaled antibiotics are acceptable)
3. Use of oral or inhaled anti-MRSA drugs within two weeks of the Screening Visit.
4. History of intolerance to inhaled vancomycin or inhaled albuterol.
5. History of intolerance to rifampin or both TMP/SMX and doxycycline.
6. Resistance to rifampin or both TMP/SMX and doxycycline at Screening.
7. Resistance to vancomycin at Screening.
8. Abnormal renal function, defined as creatinine clearance \< 50 mL/min using the Cockcroft-Gault equation for adults or Schwartz equation in children, at Screening.
9. Abnormal liver function, defined as ≥ 3x upper limit of normal (ULN), of serum aspartate transaminase (AST) or serum alanine transaminase (ALT), or known cirrhosis. at the time of Screening.
10. Serum hematology or chemistry results which in the judgment of the investigator would interfere with completion of the study.
11. History of or listed for solid organ or hematological transplantation
12. History of sputum culture with non-tuberculous Mycobacteria in the last 6 months.
13. History of sputum culture with Burkholderia Cepacia in the last year.
14. Planned continuous use of soft contact lenses while taking rifampin and no access to glasses.
15. Current use of oral corticosteroids in doses exceeding the equivalent of 10 mg prednisone a day or 20 mg prednisone every other day
16. Administration of any investigational drug or device within 28 days of Screening or within 6 half-lives of the investigational drug (whichever is longer).
17. Patients on inhaled antibiotics must have been on the same regimen for the 4 months prior to screening
18. Female patients of childbearing potential who are pregnant or lactating, or plan on becoming pregnant
19. Any serious or active medical or psychiatric illness, which in the opinion of the investigator, would interfere with patient treatment, assessment, or adherence to the protocol.

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No